All patients
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 EGFR mutation Ex19del EGFR mutation L858R Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES previous systemic treatment (%) previous systemic treatment NO (%) smoker (current or former) smoker (never) stage I stage II stage IIIa
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
lung cancer : non small cell (NSCLC), ... vs. immune chekpoint inhibitors, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CAURAL (EXPLORATORY), 2019 (REV) 0.38 [0.06; 2.54]
0.38 [0.06 ; 2.54 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable progression or deaths (PFS)detailed results CAURAL (EXPLORATORY), 2019 (REV) 0.91 [0.18; 4.64]
0.91 [0.18 ; 4.64 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable objective responses (ORR)detailed results CAURAL (EXPLORATORY), 2019 (REV) 2.22 [0.42; 11.83]
2.22 [0.42 ; 11.83 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable AE (any grade)detailed results CAURAL (EXPLORATORY), 2019 (REV) 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 0.08 [0.01; 0.77]
0.08 [0.01 ; 0.77 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable AE leading to death (grade 5)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable SAE (any grade)detailed results CAURAL (EXPLORATORY), 2019 (REV) 0.61 [0.12; 3.16]
0.61 [0.12 ; 3.16 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable STRAE (any grade)detailed results CAURAL (EXPLORATORY), 2019 (REV) 3.00 [0.09; 97.33]
3.00 [0.09 ; 97.33 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable TRAE (any grade)detailed results CAURAL (EXPLORATORY), 2019 (REV) 0.43 [0.08; 2.42]
0.43 [0.08 ; 2.42 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable TRAE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 0.14 [0.01; 2.97]
0.14 [0.01 ; 2.97 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Arthralgia AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Back pain AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Constipation AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Cough AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Diarrhoea AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 0.70 [0.02; 22.54]
0.70 [0.02 ; 22.54 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Dry skin AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Dyspnoea AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Nausea AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Neutropenia AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 0.33 [0.01; 7.94]
0.33 [0.01 ; 7.94 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Pneumonia AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 0.33 [0.01; 7.94]
0.33 [0.01 ; 7.94 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Pruritus AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Rash AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Stomatitis AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-01 17:12 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334
- treatments: 431
